Posted by Michael Wonder on 05 Sep 2025
CERo Therapeutics receives FDA fast track designation for CER-1236 in acute myeloid leukaemia
5 September 2025 - CERo Therapeutics announces that the US FDA has granted fast track designation to the Company’s lead investigational compound, CER-1236 for acute myeloid leukaemia.
This designation is in addition to the existing orphan drug designation for the compound.
